Short-term Medication of Dapagliflozin Exacerbates CCl4 Induced Acute Liver Injury

HAN Tuo,LI Ying,WANG Lixia,XU Yang,JI Jing,WANG Yiwen,LI Cheng,ZHANG Chunyan,ZHANG Yan,LI Yongqin,WANG Congxia

DOI: https://doi.org/10.7652/jdyxb202302007

2023-01-01

Abstract:Objective To investigate the role and mechanism of dapagliflozin（Dapa）, a sodium glucose cotransporter 2 inhibitor, in acute liver injury. Methods Eight-week-old C57BL6/J mice were given a single intraperitoneal injection of CCl 4 to induce acute liver injury. The mice were preventively given 5 mg/kg Dapa by gavage 24 h and 2 h before CCl 4 injection, while those in the control group were given an equal volume of solvent gavage. After 24 h, the mice were anesthetized and sacrificed. H＆E staining, plasma biochemistry, RT-q PCR, and Western blotting were used to detect the severity of liver injury and the expressions of macrophage-related genes. Results In the CCl 4 group, hepatic infiltration of inflammatory cells increased, and liver and renal functions significantly deteriorated, which was further aggravated by Dapa. CCl 4 could promote the expressions of M1 macrophages and fibrosis-related genes in the liver, but reduce those of M2 and antioxidant-related genes, and the latter was further inhibited by Dapa. In addition, the protein expression of arginase 1 decreased and that of SGLT2 increased after Dapa intervention, while NF-κB pathway did not change significantly, suggesting that Dapa might directly affect the energy metabolism homeostasis in the liver and aggravate acute liver injury induced by CCl 4 . Conclusion Dapa can exacerbate hepatic and renal damage in acute stage of liver injury, inhibit macrophages M2 polarization, and aggravate oxidative stress and inflammatory injury induced by CCl 4 .